A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery
-
Published:2021-09-17
Issue:1
Volume:12
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Crouchet Emilie, Bandiera Simonetta, Fujiwara NaotoORCID, Li Shen, El Saghire Hussein, Fernández-Vaquero Mirian, Riedl Tobias, Sun Xiaochen, Hirschfield Hadassa, Jühling Frank, Zhu ShijiaORCID, Roehlen Natascha, Ponsolles Clara, Heydmann Laura, Saviano Antonio, Qian Tongqi, Venkatesh Anu, Lupberger JoachimORCID, Verrier Eloi R.ORCID, Sojoodi Mozhdeh, Oudot Marine A., Duong François H. T., Masia Ricard, Wei Lan, Thumann Christine, Durand Sarah C., González-Motos Victor, Heide Danijela, Hetzer Jenny, Nakagawa Shigeki, Ono AtsushiORCID, Song Won-MinORCID, Higashi Takaaki, Sanchez Roberto, Kim Rosa S., Bian C. Billie, Kiani Karun, Croonenborghs Tom, Subramanian Aravind, Chung Raymond T., Straub Beate K., Schuppan Detlef, Ankavay Maliki, Cocquerel Laurence, Schaeffer Evelyne, Goossens Nicolas, Koh Anna P., Mahajan Milind, Nair Venugopalan D.ORCID, Gunasekaran Ganesh, Schwartz Myron E.ORCID, Bardeesy NabeelORCID, Shalek Alex K.ORCID, Rozenblatt-Rosen Orit, Regev AvivORCID, Felli Emanuele, Pessaux Patrick, Tanabe Kenneth K., Heikenwälder MathiasORCID, Schuster CatherineORCID, Pochet NathalieORCID, Zeisel Mirjam B.ORCID, Fuchs Bryan C.ORCID, Hoshida YujinORCID, Baumert Thomas F.ORCID
Abstract
AbstractChronic liver disease and hepatocellular carcinoma (HCC) are life-threatening diseases with limited treatment options. The lack of clinically relevant/tractable experimental models hampers therapeutic discovery. Here, we develop a simple and robust human liver cell-based system modeling a clinical prognostic liver signature (PLS) predicting long-term liver disease progression toward HCC. Using the PLS as a readout, followed by validation in nonalcoholic steatohepatitis/fibrosis/HCC animal models and patient-derived liver spheroids, we identify nizatidine, a histamine receptor H2 (HRH2) blocker, for treatment of advanced liver disease and HCC chemoprevention. Moreover, perturbation studies combined with single cell RNA-Seq analyses of patient liver tissues uncover hepatocytes and HRH2+, CLEC5Ahigh, MARCOlow liver macrophages as potential nizatidine targets. The PLS model combined with single cell RNA-Seq of patient tissues enables discovery of urgently needed targets and therapeutics for treatment of advanced liver disease and cancer prevention.
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry
Reference72 articles.
1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Ca. Cancer J. Clin. 68, 394–424 (2018). 2. Tsochatzis, E. A., Bosch, J. & Burroughs, A. K. Liver cirrhosis. Lancet Lond. Engl. 383, 1749–1761 (2014). 3. Fujiwara, N., Friedman, S. L., Goossens, N. & Hoshida, Y. Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine. J. Hepatol. 68, 526–549 (2018). 4. Goossens, N. et al. Nonalcoholic steatohepatitis is associated with increased mortality in obese patients undergoing bariatric surgery. Clin. Gastroenterol. Hepatol. 14, 1619–1628 (2016). 5. Hoshida, Y. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995–2004 (2008).
Cited by
20 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|